These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8356046)

  • 1. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.
    Furlan M; Robles R; Affolter D; Meyer D; Baillod P; Lämmle B
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7503-7. PubMed ID: 8356046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triplet structure of human von Willebrand factor.
    Fischer BE; Thomas KB; Schlokat U; Dorner F
    Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):483-8. PubMed ID: 9531488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of von Willebrand factor triplet bands towards heparin binding supports structural model.
    Fischer BE; Thomas KB; Schlokat U; Dorner F
    Eur J Haematol; 1999 Mar; 62(3):169-73. PubMed ID: 10089894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).
    Zimmerman TS; Dent JA; Ruggeri ZM; Nannini LH
    J Clin Invest; 1986 Mar; 77(3):947-51. PubMed ID: 3485111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.
    Furlan M; Robles R; Lämmle B
    Blood; 1996 May; 87(10):4223-34. PubMed ID: 8639781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophoretic and functional characteristics of the von Willebrand factor in human fetal plasma.
    Mazurier C; Daffos F; Forestier F
    Br J Haematol; 1992 Jun; 81(2):263-70. PubMed ID: 1643023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.
    Fischer BE; Schlokat U; Mitterer A; Reiter M; Mundt W; Turecek PL; Schwarz HP; Dorner F
    FEBS Lett; 1995 Nov; 375(3):259-62. PubMed ID: 7498512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis.
    Mazurier C; Samor B; Goudemand M
    Thromb Haemost; 1986 Feb; 55(1):61-4. PubMed ID: 3486491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y; Rick ME
    Proc Natl Acad Sci U S A; 1985 Sep; 82(17):5968-72. PubMed ID: 2994057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo.
    Hamilton KK; Fretto LJ; Grierson DS; McKee PA
    J Clin Invest; 1985 Jul; 76(1):261-70. PubMed ID: 3160727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.
    Layet S; Girma JP; Obert B; Peynaud-Debayle E; Bihoreau N; Meyer D
    Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):129-37. PubMed ID: 1531749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.
    Dent JA; Galbusera M; Ruggeri ZM
    J Clin Invest; 1991 Sep; 88(3):774-82. PubMed ID: 1909351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway.
    Tsai HM; Nagel RL; Hatcher VB; Seaton AC; Sussman II
    Br J Haematol; 1991 Oct; 79(2):239-45. PubMed ID: 1958482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native multimer analysis of plasma and platelet von Willebrand factor compared to denaturing separation: implication for the interpretation of satellite bands.
    Hohenstein K; Griesmacher A; Weigel G; Golderer G; Ott HW
    Electrophoresis; 2011 Jun; 32(13):1684-91. PubMed ID: 21647922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis.
    Federici AB; Berkowitz SD; Lattuada A; Mannucci PM
    Blood; 1993 Feb; 81(3):720-5. PubMed ID: 8427964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An explanation for minor multimer species in endothelial cell-synthesized von Willebrand factor.
    Lynch DC; Zimmerman TS; Ling EH; Browning PJ
    J Clin Invest; 1986 Jun; 77(6):2048-51. PubMed ID: 3486890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu--evidence of the importance of the multimerization degree of vWF.
    de Romeuf C; Mazurier C
    Thromb Haemost; 1993 May; 69(5):436-40. PubMed ID: 8322266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain.
    Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM
    Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor.
    Bockenstedt P; Greenberg JM; Handin RI
    J Clin Invest; 1986 Mar; 77(3):743-9. PubMed ID: 2936763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.